Solid Biosciences Inc.
SLDBDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SLDB's past catalysts played out
SGT-003
Duchenne Muscular Dystrophy
trofosfamide, idarubicin, etoposide
Soft Tissue Sarcoma
genexolPM + cisplatin
Locally Advanced Head and Neck Squamous Cell Carcinoma
Cetuximab
Head and Neck Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SGT-003 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
trofosfamide, idarubicin, etoposide | Phase 3 | Soft Tissue Sarcoma | - | - |
genexolPM + cisplatin | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
Cetuximab | Phase 2 | Head and Neck Neoplasm | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Solid Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Solid Biosciences Inc.'s (SLDB) pipeline across Phase 3, Phase 2. Its lead program is SGT-003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Solid Biosciences Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Solid Biosciences Inc. (SLDB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SLDB biotech catalysts?→
Add SLDB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Solid Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.